Extract of the Chinese herbal formula Huo Luo Xiao Ling Dan inhibited adjuvant arthritis in rats

Journal of Ethnopharmacology

Volumn 121, Issue 3, 2009, Pages 366-371

  Zhang, Rui Xin ^a   Fan, Arthur Yin ^a   Zhou, An Nan ^a   Moudgil, Kamal D ^a   Ma, Zhong Ze ^b   Lee, David Yue Wei ^b   Fong, Harry H S ^c   Berman, Brian M ^a   Lao, Lixing ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MCLEAN HOSPITAL   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Arthritis; Chinese herbs; IL 1 ; Rats; TNF

Indexed keywords

FREUND ADJUVANT; HUO LUO XIAO LING DAN; INTERLEUKIN 1BETA; PLANT EXTRACT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BEHAVIOR CHANGE; CHINESE HERB; CHINESE MEDICINE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG ISOLATION; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; MALE; NONHUMAN; PARAMETER; PAW EDEMA; RAT; SCORING SYSTEM; SKIN INDURATION; TISSUE LEVEL;

ANGIOSPERMS; ANIMALS; ARTHRITIS, EXPERIMENTAL; DRUGS, CHINESE HERBAL; EDEMA; FOOT; FREUND'S ADJUVANT; INTERLEUKIN-1BETA; MALE; PHYTOTHERAPY; PLANT EXTRACTS; RATS; RATS, INBRED LEW; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; MYCOBACTERIUM TUBERCULOSIS; RATTUS;

EID: 58149270873     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2008.11.018     Document Type: Article

References (36)

1. Barnes P.M., Powell-Griner E., McFann K., and Nahin R.L. Complementary and Alternative Medicine Use Among Adults 2002 (2004), Advance Data From Vital and Health Statistics, United States
2. Bensky D., and Barolet R. Chinese Herbal Medicine: Formulas & Strategies (1990), Eastland Press, Seattle
3. Bensky D., and Gamble A. Chinese Herbal Medicine: Materia Medica. revised edition (1993), Eastland Press, Seattle, Washington
4. Chandrashekara S., Anilkumar T., and Jamuna S. Complementary and alternative drug therapy in arthritis. Journal of the Association of Physicians of India 50 (2002) 225-227
5. China State Administration of Traditional Chinese Medicine, 1999. testing guidelines for safety evaluation of new drug, The Guidelines for Developing New Chinese Herbal Medicine. Beijing.
6. Davies N.M., and Jamali F. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. Journal of Pharmacy & Pharmaceutical Sciences 7 (2004) 332-336
7. Durai M., Kim H.R., and Moudgil K.D. The regulatory C-terminal determinants within mycobacterial heat shock protein 65 are cryptic and cross-reactive with the dominant self homologs: implications for the pathogenesis of autoimmune arthritis. Journal of Immunology 173 (2004) 181-188
8. FDA, 2002. Guidance for industry and reviewers: estimate the safe starting dose in clinical trials for therapeutics in adult healthy volunteers, Appendix A (Draft Guidance)http://www.fda.gov/cber/gdlns/dose.htm.
9. FDA, 2004. Center for Drug Evaluation and Research (CDER), Guidance for industry: botanic drug products, www.fda.gov/cder/guidance/4592fnl.htm.
10. Fleischmann R., Stern R., and Iqbal I. Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy 4 (2004) 1333-1344
11. Gad S.C. Drug Safety Evaluation (2002), Wiley-Interscience, New York
12. Grand Pharmacopeia of Chinese Materia Medica Editing Committee. Grand Pharmacopeia of Chinese Materia Medica (Zhong Hua Ben Cao) (1999), Shanghai Scientific Press, Shanghai
13. Harris Jr. E.D. Rheumatoid arthritis, pathophysiology and implications for therapy. New England Journal of Medicine 322 (1990) 1277-1289
14. Ho L.J., and Lai J.H. Chinese herbs as immunomodulators and potential disease-modifying antirheumatic drugs in autoimmune disorders. Current Drug Metabolism 5 (2004) 181-192
15. Jacques C., Gosset M., Berenbaum F., and Gabay C. The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. Vitamins & Hormones 74 (2006) 371-403
16. Kobayashi S., Miyamoto T., Kimura I., and Kimura M. Inhibitory effect of isoliquiritin, a compound in licorice root, on angiogenesis in vivo and tube formation in vitro. Biological & Pharmaceutical Bulletin 18 (1995) 1382-1386
17. Kvien T.K. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 22 (2004) 1-12
18. Lao L., Fan A.Y., Zhang R.-X., Zhou A.N., Ma Z.Z., Lee D.Y.-W.K., and Berman R.B. Anti-hyperalgesic and anti-inflammatory effects of the modified Chinese herbal formula Huo Luo Xiao Ling Dan (HLXL) in Rats. American Journal of Chinese Medicine 34 (2006) 833-844
19. Leem K., Kim H., Boo Y., Lee H.S., Kim J.S., Yoo Y.C., Ahn H.J., Park H.J., Seo J.C., Kim H.K., Jin S.Y., Park H.K., Chung J.H., and Cho J.J. Effects of Paeonia lactiflora root extracts on the secretions of monocyte chemotactic protein-1 and -3 in human nasal fibroblasts. Phytotherapy Research 18 (2004) 241-243
20. Liang Y.Y. The relation between rheumatoid arthritis and TCM blood stagnation syndrome. Traditional Chinese Medicine Research 10 (1997) 1-3
21. Liu S.P., Dong W.G., Wu D.F., Luo H.S., and Yu J.P. Protective effect of Angelica sinensis polysaccharide on experimental immunological colon injury in rats. World Journal of Gastroenterology 9 (2003) 2786-2790
22. In: Loeb W.F., and FW Q. (Eds). The Clinical Chemistry of Laboratory Animals. 2nd ed. (1999), Taylor & Francis, Philadelphia
23. Ozaki Y. Antiinflammatory effect of tetramethylpyrazine and ferulic acid. Chemical & Pharmaceutical Bulletin 40 (1992) 954-956
24. Peng H.R. Grand Dictionary of Chinese Medicinal Formula (Zhong Yi Fang Ji Da Ci Dian) (1998), People's Health Press, Beijing
25. Safayhi H., Mack T., Sabieraj J., Anazodo M.I., Subramanian L.R., and Ammon H.P. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. Journal of Pharmacology & Experimental Therapeutics 261 (1992) 1143-1146
26. Scheiman J.M. The impact of nonsteroidal anti-inflammatory drug-induced gastropathy. American Journal of Managed Care 7 (2001) S10-14
27. Sharma M.L., Bani S., and Singh G.B. Anti-arthritic activity of boswellic acids in bovine serum albumin (BSA)-induced arthritis. International Journal of Immunopharmacology 11 (1989) 647-652
28. Smith-Oliver T., Noel L.S., Stimpson S.S., Yarnall D.P., and Connolly K.M. Elevated levels of TNF in the joints of adjuvant arthritic rats. Cytokine 5 (1993) 298-304
29. Sun, S.M., 682. Thousand Ducat Prescriptions (Qian Jing Fan).
30. Syrovets T., Buchele B., Krauss C., Laumonnier Y., and Simmet T. Acetyl-boswellic acids inhibit lipopolysaccharide-mediated TNF-alpha induction in monocytes by direct interaction with IkappaB kinases. Journal of Immunology 174 (2005) 498-506
31. Taurog J.D., Argentieri D.C., and McReynolds R.A. Adjuvant arthritis. Methods in Enzymology 162 (1988) 339-355
32. The Pharmacopoeia Commission of PRC. Pharmacopoeia of the People's Republic of China (2000), Chemical Industry Press, Beijing
33. Wang Y.C., Ji S.Y., and Wang R. The clinical application of Huo Luo Xiao Ling Dan. Acta Traditional Chinese Medicine 30 (2002) 53
34. Wei Y.H., Li Y., and Qiang C.J. Effects and mechanisms of FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor, on adjuvant arthritis in rats. International Immunopharmacology 4 (2004) 1625-1632
35. White House Commission on Complementary and Alternative Medicine, 2002. White House Commission on Complementary and Alternative Medicine Policy. http://www.whccamp.hhs.gov/finalreport.html.
36. Zhang X.C. Yi Xue Zhong Zhong Can Xi Lu/Records of Heart-felt Experiences in Medicine with the Reference to the West (1974), Hebei people's Publisher, Shijiazhuang